Targeting growth factors and angiogenesis; using small molecules in malignancy

Harold J. Wanebo, Athanassios Argiris, Emily Bergsland, Sanjiv Agarwala, Hope Rugo

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Targeted biologic therapy for cancer has evolved from the laboratory to active clinical protocols and applied clinical practice in selected patients. Major targets include epidermal growth factor, and vascular endothelial growth factor receptors which are commonly expressed in gastro-intestinal cancers head & neck and lung cancers, and to some degree breast and gynecologic malignancy. Down stream signal transduction pathway inhibition of B-raf and N-ras mutations are examined in melanoma. New approaches involving re-packaging of chemotherapeutic agents are being exemplified in the nanoparticle formulation of prclitaxel which provides increased access to endothelial and tumor cells with potential enhanced therapeutic efficacy compared to the conventional version solubilized in a cremophor.

Original languageEnglish (US)
Pages (from-to)279-292
Number of pages14
JournalCancer and Metastasis Reviews
Volume25
Issue number2
DOIs
StatePublished - Jun 1 2006
Externally publishedYes

    Fingerprint

Keywords

  • Angiogenesis
  • Growth factors
  • Oncologic targeting
  • Small molecules

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this